Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/02/2025 08:18 PDT] PCRX Expected to Trade Down Short Term
• [06/09/2025 07:25 PDT] PCRX, Expected to Trade Lower After Bearish Insider Trading
• [06/06/2025 07:23 PDT] PCRX, Expected to Trade Lower After Bearish Insider Trading
• [05/27/2025 07:25 PDT] PCRX Expected to Trade Up After Bullish Patterns Develop
• [05/23/2025 07:49 PDT] PCRX Expected to Trade Up After Bullish Patterns Develop
• [05/15/2025 16:12 PDT] Pacira BioSciences, Inc. (NASDAQ:PCRX), Up By 100% ($23.4) From $23.4 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/15/2025 06:53 PDT] PCRX Expected to Trade Up After Bullish Patterns Develop
• [05/13/2025 07:09 PDT] PCRX Expected to Trade Up After Bullish Patterns Develop